Report Detail

Other Global Neurodegenerative Disease Treatment Market Size, Status and Forecast 2020-2026

  • RnM4274610
  • |
  • 30 December, 2020
  • |
  • Global
  • |
  • 99 Pages
  • |
  • QYResearch
  • |
  • Other

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Market Analysis by Type
    • 1.3.1 Global Neurodegenerative Disease Treatment Market Size Growth Rate by Type: 2020 VS 2026
    • 1.3.2 Neurotransmitter Agents
    • 1.3.3 Neuroprotective Agents
    • 1.3.4 Biologics
    • 1.3.5 Others
  • 1.4 Market by Application
    • 1.4.1 Global Neurodegenerative Disease Treatment Market Share by Application: 2020 VS 2026
    • 1.4.2 Multiple Sclerosis [MS]
    • 1.4.3 Alzheimer’s Disease
    • 1.4.4 Parkinson's Disease
    • 1.4.5 Acute Migraine
    • 1.4.6 Autism
    • 1.4.7 Narcolepsy
    • 1.4.8 Amyotrophic Lateral Sclerosis [ALS]
    • 1.4.9 Attention Deficit Hyperactivity Disorder [ADHD]
    • 1.4.10 Spinal Muscular Atrophy
    • 1.4.11 Huntington's Disease
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Global Growth Trends

  • 2.1 Global Neurodegenerative Disease Treatment Market Perspective (2015-2026)
  • 2.2 Neurodegenerative Disease Treatment Growth Trends by Regions
    • 2.2.1 Neurodegenerative Disease Treatment Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Neurodegenerative Disease Treatment Historic Market Share by Regions (2015-2020)
    • 2.2.3 Neurodegenerative Disease Treatment Forecasted Market Size by Regions (2021-2026)
  • 2.3 Neurodegenerative Disease Treatment Industry Dynamic
    • 2.3.1 Neurodegenerative Disease Treatment Market Trends
    • 2.3.2 Neurodegenerative Disease Treatment Market Drivers
    • 2.3.3 Neurodegenerative Disease Treatment Market Challenges
    • 2.3.4 Neurodegenerative Disease Treatment Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Neurodegenerative Disease Treatment Players by Market Size
    • 3.1.1 Global Top Neurodegenerative Disease Treatment Players by Revenue (2015-2020)
    • 3.1.2 Global Neurodegenerative Disease Treatment Revenue Market Share by Players (2015-2020)
  • 3.2 Global Neurodegenerative Disease Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Neurodegenerative Disease Treatment Revenue
  • 3.4 Global Neurodegenerative Disease Treatment Market Concentration Ratio
    • 3.4.1 Global Neurodegenerative Disease Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Disease Treatment Revenue in 2019
  • 3.5 Key Players Neurodegenerative Disease Treatment Area Served
  • 3.6 Key Players Neurodegenerative Disease Treatment Product Solution and Service
  • 3.7 Date of Enter into Neurodegenerative Disease Treatment Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Neurodegenerative Disease Treatment Breakdown Data by Type

  • 4.1 Global Neurodegenerative Disease Treatment Historic Market Size by Type (2015-2020)
  • 4.2 Global Neurodegenerative Disease Treatment Forecasted Market Size by Type (2021-2026)

5 Neurodegenerative Disease Treatment Breakdown Data by Application

  • 5.1 Global Neurodegenerative Disease Treatment Historic Market Size by Application (2015-2020)
  • 5.2 Global Neurodegenerative Disease Treatment Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Neurodegenerative Disease Treatment Market Size (2015-2026)
  • 6.2 North America Neurodegenerative Disease Treatment Market Size by Type (2015-2020)
  • 6.3 North America Neurodegenerative Disease Treatment Market Size by Application (2015-2020)
  • 6.4 North America Neurodegenerative Disease Treatment Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe Neurodegenerative Disease Treatment Market Size (2015-2026)
  • 7.2 Europe Neurodegenerative Disease Treatment Market Size by Type (2015-2020)
  • 7.3 Europe Neurodegenerative Disease Treatment Market Size by Application (2015-2020)
  • 7.4 Europe Neurodegenerative Disease Treatment Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic

8 Asia-Pacific

  • 8.1 Asia-Pacific Neurodegenerative Disease Treatment Market Size (2015-2026)
  • 8.2 Asia-Pacific Neurodegenerative Disease Treatment Market Size by Type (2015-2020)
  • 8.3 Asia-Pacific Neurodegenerative Disease Treatment Market Size by Application (2015-2020)
  • 8.4 Asia-Pacific Neurodegenerative Disease Treatment Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia

9 Latin America

  • 9.1 Latin America Neurodegenerative Disease Treatment Market Size (2015-2026)
  • 9.2 Latin America Neurodegenerative Disease Treatment Market Size by Type (2015-2020)
  • 9.3 Latin America Neurodegenerative Disease Treatment Market Size by Application (2015-2020)
  • 9.4 Latin America Neurodegenerative Disease Treatment Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 Middle East & Africa

  • 10.1 Middle East & Africa Neurodegenerative Disease Treatment Market Size (2015-2026)
  • 10.2 Middle East & Africa Neurodegenerative Disease Treatment Market Size by Type (2015-2020)
  • 10.3 Middle East & Africa Neurodegenerative Disease Treatment Market Size by Application (2015-2020)
  • 10.4 Middle East & Africa Neurodegenerative Disease Treatment Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE

11Key Players Profiles

  • 11.1 Allergan plc
    • 11.1.1 Allergan plc Company Details
    • 11.1.2 Allergan plc Business Overview
    • 11.1.3 Allergan plc Neurodegenerative Disease Treatment Introduction
    • 11.1.4 Allergan plc Revenue in Neurodegenerative Disease Treatment Business (2015-2020))
    • 11.1.5 Allergan plc Recent Development
  • 11.2 Bayer AG
    • 11.2.1 Bayer AG Company Details
    • 11.2.2 Bayer AG Business Overview
    • 11.2.3 Bayer AG Neurodegenerative Disease Treatment Introduction
    • 11.2.4 Bayer AG Revenue in Neurodegenerative Disease Treatment Business (2015-2020)
    • 11.2.5 Bayer AG Recent Development
  • 11.3 F. Hoffmann La-Roche Ltd.
    • 11.3.1 F. Hoffmann La-Roche Ltd. Company Details
    • 11.3.2 F. Hoffmann La-Roche Ltd. Business Overview
    • 11.3.3 F. Hoffmann La-Roche Ltd. Neurodegenerative Disease Treatment Introduction
    • 11.3.4 F. Hoffmann La-Roche Ltd. Revenue in Neurodegenerative Disease Treatment Business (2015-2020)
    • 11.3.5 F. Hoffmann La-Roche Ltd. Recent Development
  • 11.4 GlaxoSmithKline plc
    • 11.4.1 GlaxoSmithKline plc Company Details
    • 11.4.2 GlaxoSmithKline plc Business Overview
    • 11.4.3 GlaxoSmithKline plc Neurodegenerative Disease Treatment Introduction
    • 11.4.4 GlaxoSmithKline plc Revenue in Neurodegenerative Disease Treatment Business (2015-2020)
    • 11.4.5 GlaxoSmithKline plc Recent Development
  • 11.5 Johnson & Johnson
    • 11.5.1 Johnson & Johnson Company Details
    • 11.5.2 Johnson & Johnson Business Overview
    • 11.5.3 Johnson & Johnson Neurodegenerative Disease Treatment Introduction
    • 11.5.4 Johnson & Johnson Revenue in Neurodegenerative Disease Treatment Business (2015-2020)
    • 11.5.5 Johnson & Johnson Recent Development
  • 11.6 Merck KGaA
    • 11.6.1 Merck KGaA Company Details
    • 11.6.2 Merck KGaA Business Overview
    • 11.6.3 Merck KGaA Neurodegenerative Disease Treatment Introduction
    • 11.6.4 Merck KGaA Revenue in Neurodegenerative Disease Treatment Business (2015-2020)
    • 11.6.5 Merck KGaA Recent Development
  • 11.7 Novartis AG
    • 11.7.1 Novartis AG Company Details
    • 11.7.2 Novartis AG Business Overview
    • 11.7.3 Novartis AG Neurodegenerative Disease Treatment Introduction
    • 11.7.4 Novartis AG Revenue in Neurodegenerative Disease Treatment Business (2015-2020)
    • 11.7.5 Novartis AG Recent Development
  • 11.8 Pfizer, Inc.
    • 11.8.1 Pfizer, Inc. Company Details
    • 11.8.2 Pfizer, Inc. Business Overview
    • 11.8.3 Pfizer, Inc. Neurodegenerative Disease Treatment Introduction
    • 11.8.4 Pfizer, Inc. Revenue in Neurodegenerative Disease Treatment Business (2015-2020)
    • 11.8.5 Pfizer, Inc. Recent Development
  • 11.9 Sanofi
    • 11.9.1 Sanofi Company Details
    • 11.9.2 Sanofi Business Overview
    • 11.9.3 Sanofi Neurodegenerative Disease Treatment Introduction
    • 11.9.4 Sanofi Revenue in Neurodegenerative Disease Treatment Business (2015-2020)
    • 11.9.5 Sanofi Recent Development
  • 11.10 Teva Pharmaceutical Industries Ltd.
    • 11.10.1 Teva Pharmaceutical Industries Ltd. Company Details
    • 11.10.2 Teva Pharmaceutical Industries Ltd. Business Overview
    • 11.10.3 Teva Pharmaceutical Industries Ltd. Neurodegenerative Disease Treatment Introduction
    • 11.10.4 Teva Pharmaceutical Industries Ltd. Revenue in Neurodegenerative Disease Treatment Business (2015-2020)
    • 11.10.5 Teva Pharmaceutical Industries Ltd. Recent Development

12Analyst's Viewpoints/Conclusions

    13Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Neurodegenerative Disease Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Neurodegenerative Disease Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    Market segment by Type, the product can be split into
    Neurotransmitter Agents
    Neuroprotective Agents
    Biologics
    Others

    Market segment by Application, split into
    Multiple Sclerosis [MS]
    Alzheimer’s Disease
    Parkinson's Disease
    Acute Migraine
    Autism
    Narcolepsy
    Amyotrophic Lateral Sclerosis [ALS]
    Attention Deficit Hyperactivity Disorder [ADHD]
    Spinal Muscular Atrophy

    Based on regional and country-level analysis, the Neurodegenerative Disease Treatment market has been segmented as follows:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE

    In the competitive analysis section of the report, leading as well as prominent players of the global Neurodegenerative Disease Treatment market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    The key players covered in this study
    Allergan plc
    Bayer AG
    F. Hoffmann La-Roche Ltd.
    GlaxoSmithKline plc
    Johnson & Johnson
    Merck KGaA
    Novartis AG
    Pfizer, Inc.
    Sanofi


    Summary:
    Get latest Market Research Reports on Neurodegenerative Disease Treatment. Industry analysis & Market Report on Neurodegenerative Disease Treatment is a syndicated market report, published as Global Neurodegenerative Disease Treatment Market Size, Status and Forecast 2020-2026. It is complete Research Study and Industry Analysis of Neurodegenerative Disease Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    $3,900.00
    $5,850.00
    $7,800.00
    2,844.67
    4,267.01
    5,689.34
    3,216.61
    4,824.92
    6,433.23
    405,580.50
    608,370.75
    811,161.00
    284,636.04
    426,954.06
    569,272.08
    Credit card Logo

    Related Reports


    Reason to Buy

    Request for Sample of this report